126 related articles for article (PubMed ID: 35083783)
1. Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing.
Hertz DL; Chen L; Henry NL; Griggs JJ; Hayes DF; Derstine BA; Su GL; Wang SC; Pai MP
Br J Clin Pharmacol; 2022 Jul; 88(7):3222-3229. PubMed ID: 35083783
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.
Hertz DL; Kidwell KM; Vangipuram K; Li F; Pai MP; Burness M; Griggs JJ; Schott AF; Van Poznak C; Hayes DF; Lavoie Smith EM; Henry NL
Clin Cancer Res; 2018 Aug; 24(15):3602-3610. PubMed ID: 29703818
[No Abstract] [Full Text] [Related]
3. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
Sánchez-Barroso L; Apellaniz-Ruiz M; Gutiérrez-Gutiérrez G; Santos M; Roldán-Romero JM; Curras M; Remacha L; Calsina B; Calvo I; Sereno M; Merino M; García-Donas J; Castelo B; Guerra E; Letón R; Montero-Conde C; Cascón A; Inglada-Pérez L; Robledo M; Rodríguez-Antona C
Oncologist; 2019 Aug; 24(8):e784-e792. PubMed ID: 30470691
[TBL] [Abstract][Full Text] [Related]
6. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel.
Youn S; Chen A; Ha V; Chambers C; Eurich DT; McCall M; Sawyer MB
Clin Nutr; 2021 Aug; 40(8):4888-4892. PubMed ID: 34358833
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS
Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients.
Robertson J; Raizer J; Hodges JS; Gradishar W; Allen JA
J Peripher Nerv Syst; 2018 Jun; 23(2):129-133. PubMed ID: 29696771
[TBL] [Abstract][Full Text] [Related]
9. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
Openshaw H; Beamon K; Synold TW; Longmate J; Slatkin NE; Doroshow JH; Forman S; Margolin K; Morgan R; Shibata S; Somlo G
Clin Cancer Res; 2004 Jan; 10(2):461-7. PubMed ID: 14760066
[TBL] [Abstract][Full Text] [Related]
10. Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors.
Ojara FW; Henrich A; Frances N; Huisinga W; Hartung N; Joerger M; Kloft C
J Pharmacol Exp Ther; 2020 Dec; 375(3):430-438. PubMed ID: 33008871
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
Tamura T; Sasaki Y; Nishiwaki Y; Saijo N
Jpn J Cancer Res; 1995 Dec; 86(12):1203-9. PubMed ID: 8636011
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability.
Chen L; Chen CS; Sun Y; Henry NL; Stringer KA; Hertz DL
Cancer Chemother Pharmacol; 2021 Sep; 88(3):475-483. PubMed ID: 34089352
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
15. Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
Hertz DL
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):227-239. PubMed ID: 33401943
[No Abstract] [Full Text] [Related]
16. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
17. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
Seidman AD; Hudis CA; Albanell J; Tong W; Tepler I; Currie V; Moynahan ME; Theodoulou M; Gollub M; Baselga J; Norton L
J Clin Oncol; 1998 Oct; 16(10):3353-61. PubMed ID: 9779712
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Ghoreishi Z; Keshavarz S; Asghari Jafarabadi M; Fathifar Z; Goodman KA; Esfahani A
BMC Cancer; 2018 Oct; 18(1):958. PubMed ID: 30290775
[TBL] [Abstract][Full Text] [Related]
19. Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer.
Chan YN; Jheng YW; Wang PJ; Chen CY; Lin MW; Wang YJ
Clin J Oncol Nurs; 2019 Oct; 23(5):494-501. PubMed ID: 31538967
[TBL] [Abstract][Full Text] [Related]
20. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
Baldwin RM; Owzar K; Zembutsu H; Chhibber A; Kubo M; Jiang C; Watson D; Eclov RJ; Mefford J; McLeod HL; Friedman PN; Hudis CA; Winer EP; Jorgenson EM; Witte JS; Shulman LN; Nakamura Y; Ratain MJ; Kroetz DL
Clin Cancer Res; 2012 Sep; 18(18):5099-109. PubMed ID: 22843789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]